Indefinite Delivery Contract HHSD200201357339I

The National Institute of Child Health and Human Development awarded an indefinite-delivery contract to Westat, Inc. with a ceiling of $175 million on June 1, 2023, for International and Domestic Pediatric and Maternal HIV Studies and Other Highly Infectious Diseases. This is a single-award vehicle with ultimate completion on May 31, 2030, carrying no set-aside designation. Work is performed at Westat's facilities in Rockville and Potomac, Maryland. The IDIQ supports a data coordinating center...

The Agency for Healthcare Research and Quality (AHRQ), a civilian federal agency, awarded a multiple award indefinite delivery contract (IDC) titled "Accelerating Change and Transformation in Organizations and Networks IV (ACTION IV)" to Research Triangle Institute (RTI) International, a nonprofit research institute. The $5 million ceiling IDC has a period of performance through May 26, 2025. Under this IDC, AHRQ has issued two task orders to RTI. The first, a $2,285,400...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, has awarded a $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Southern Research Institute, a non-profit research organization, to provide preclinical development support for candidate products and drug development activities related to HIV therapeutics. The contract does not have a set-aside designation and has a period of...

Mission Analytics Group, Inc., a woman-owned small business, was awarded a single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at $344.7 million by the Health Resources and Services Administration (HRSA), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract, which runs from September 25, 2024, through September 24, 2026, with no set-aside designation, establishes a vehicle for Mission Analytics Group to provide comprehensive...

The National Institute of Allergy and Infectious Diseases awarded multiple indefinite delivery/indefinite quantity contracts to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The scope of work encompasses seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation...

The Centers for Disease Control and Prevention (CDC) awarded a series of firm-fixed-price delivery order contracts under an Indefinite Delivery Contract (IDC) to the non-profit Research Triangle Institute (RTI) International for the "Economic Evaluation of HIV Prevention Interventions." The IDC ceiling value is $3,200,000, with individual delivery orders ranging from $127,657 to $824,940. RTI, a research organization with expertise across public health, economics, and data analysis,...

The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027. Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop...

JSI Research & Training Institute Inc., a non-profit organization specializing in global health, public health, and program implementation services, was awarded a single-award Indefinite Delivery Contract (IDIQ) by the Health Resources and Services Administration (HRSA), a civilian federal agency. The contract, valued at $344.7 million with a completion date of September 25, 2026, was awarded on September 26, 2024, under the "Evaluations and Evidence Building IDIQ" program. The...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $107,274,471 to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B and C, and tuberculosis. This multiple-award IDIQ contract has a 7-year period of performance from October 2020 to October 2027. The scope...

The National Institute of Allergy and Infectious Diseases awarded an indefinite-delivery contract to Lovelace Biomedical Research Institute with a ceiling of $98,878,757 on April 15, 2023, as a multiple-award vehicle under the Resources to Advance Pediatrics and HIV Prevention Science program. The contract carries no set-aside designation and extends through April 14, 2030. Performance takes place in Albuquerque, New Mexico. The originating pre-solicitation, posted February 18, 2022, sought...